IBJNews

Lilly licenses Xigris rights to new biotech firm

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created biotech company that will seek to reinvigorate sales of the medication, the Indianapolis-based drugmaker announced Monday morning.

The new company, BioCritica Inc., will be based in central Indiana and will be jointly owned by Lilly and two private investment firms: New Jersey-based Care Capital LLC and North Carolina-based NovaQuest Capital Management LLC.

The company will be led by David Broecker, who managed Lilly manufacturing operations in Germany and Ireland before becoming CEO of Alkermes Inc., a Massachusetts-based drug development firm.

A “handful” of Lilly employees will leave Lilly to join BioCritica, Broecker said. He expects the company to employ 20 to 25 people by year's end and as many as 70 by 2015.

The deal was structured with help from Indianapolis-based BioCrossroads, a life sciences business development group. Also, the Indiana Economic Development Corp. committed $2.9 million in tax credits and $175,000 in training grants.

BioCritica hopes to be able to do the clinical trial work necessary to develop Xigris for additional uses other than its treatment of severe sepsis in hospital patients. Within Lilly, Xigris was well down the priority list to get time from scientists and other staff.

“It’s a good way for the molecule to get some resources that it might not otherwise be able to get [inside Lilly],” said Lilly spokesman Mark Taylor.

Lilly, which is trying to find new drugs to replace aging blockbusters, has nearly 70 molecules in clinical trials, and is desperately seeking drugs that can produce annual sales of $500 million or more.

Xigris’ low-priority status within Lilly has much to do with its rather paltry sales, which totaled $104 million last year, down 18 percent from the previous year.

Xigris was the first drug Lilly launched after it lost patent protection on its best-seller Prozac in 2001. It is the only drug approved in the United States to fight severe sepsis. Lilly fought a long legal battle over the drug's patent with Massachusetts-based Ariad Pharmaceuticals Inc.

Expectations for the drug were initially huge, with some Wall Street analysts predicting annual sales of $2 billion. But the drug struggled after U.S. regulators approved the drug for a small category of patients, and because hospitals struggled to identify which patients and in which situations the drug was appropriate.

But Broecker hopes a new clinical trial Lilly sponsored, which is scheduled to produce results by year's end, will clear up that confusion.

"We believe if it's favorable, it will allow us to go out and essentially re-energize the marketplace," Broecker said.

BioCritica also plans to license and sell other drugs for use in critical care patients in hospitals.

“We are confident that BioCritica will help realize the full potential for Xigris while working to develop new critical care medicines,” said Lilly CEO John Lechleiter, in a statement.

Lilly did not disclose the financial terms of the deal, nor how much equity it will hold in BioCritica. Tayor said BioCritica will have an option to acquire the international rights to Xigris at a later date.

Taylor said the deal will have minimal impact on Lilly’s work force, since Xigris is manufactured by third-party firms and is sold via a contract sales force. Lilly does and will continue to do the packaging of Xigris.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Looking at the two companies - in spite of their relative size to one another -- Ricker's image is (by all accounts) pretty solid and reputable. Their locations are clean, employees are friendly and the products they offer are reasonably priced. By contrast, BP locations are all over the place and their reputation is poor, especially when you consider this is the same "company" whose disastrous oil spill and their response was nothing short of irresponsible should tell you a lot. The fact you also have people who are experienced in franchising saying their system/strategy is flawed is a good indication that another "spill" has occurred and it's the AM-PM/Ricker's customers/company that are having to deal with it.

  2. Daniel Lilly - Glad to hear about your points and miles. Enjoy Wisconsin and Illinois. You don't care one whit about financial discipline, which is why you will blast the "GOP". Classic liberalism.

  3. Isn't the real reason the terrain? The planners under-estimated the undulating terrain, sink holes, karst features, etc. This portion of the route was flawed from the beginning.

  4. You thought no Indy was bad, how's no fans working out for you? THe IRl No direct competition and still no fans. Hey George Family, spend another billion dollars, that will fix it.

  5. I live downtown Indy and had to be in downtown Chicago for a meeting. In other words, I am the target demographic for this train. It leaves at 6:00-- early but doable. Then I saw it takes 5+ hours. No way. I drove. I'm sure I paid 3 to 5 times as much once you factor in gas, parking, and tolls, but it was reimbursed so not a factor for me. Any business traveler is going to take the option that gets there quickly and reliably... and leisure travelers are going to take the option that has a good schedule and promotional prices (i.e., Megabus). Indy to Chicago is the right distance (too short to fly but takes several hours to drive) that this train could be extremely successful even without subsidies, if they could figure out how to have several frequencies (at least 3x/day) and make the trip in a reasonable amount of time. For those who have never lived on the east coast-- Amtrak is the #1 choice for NY-DC and NY-Boston. They have the Acela service, it runs almost every hour, and it takes you from downtown to downtown. It beats driving and flying hands down. It is too bad that we cannot build something like this in the midwest, at least to connect the bigger cities.

ADVERTISEMENT